氯甲基(4-硝基苯基)碳酸酯 | 50780-50-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 氯甲基(4-硝基苯基)碳酸酯
• 英文名称: 4-chloromethoxycarbonyloxy-1-nitrobenzene
• 英文别名: carbonic acid chloromethyl ester 4-nitrophenyl ester；2-chloromethyl-p-nitrophenyl carbonate；chloromethyl (4-nitrophenyl)carbonate；chloromethyl 4-nitrophenyl carbonate；chloromethyl p-nitrophenyl carbonate；chloromethyl-4-nitrophenyl carbonate；Chloromethyl (4-nitrophenyl) carbonate
• CAS: 50780-50-2
• 化学式: C₈H₆ClNO₅
• mdl: MFCD00208111
• 分子量: 231.592
• InChiKey: PDTWCUYBIVJSTL-UHFFFAOYSA-N

物化性质

• 熔点：
  56-58 °C(Solv: isopropyl ether (108-20-3); hexane (110-54-3))
• 沸点：
  356.5±42.0 °C(Predicted)
• 密度：
  1.478±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2920909090

反应信息

• 作为反应物：
  描述：

  氯甲基(4-硝基苯基)碳酸酯 在 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 37.0h， 生成
  参考文献：
  名称：

  Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation

  摘要：

  The objective of this work was to synthesize cyclic prodrug 2 derived from the parent RGD peptidomimetic 1 and to evaluate its chemical and enzymatic stabilities and antithrombic activity. Cyclic prodrug 2 was formed to improve the cell membrane permeation of RGD peptidomimetic 1 by transiently masking the unfavorable physicochemical properties of compound 1. Cyclic prodrug 2 was synthesized by linking the amino and carboxylic acid groups of parent 1 via the (acyloxy)alkoxy promoiety. The prodrug-to-drug conversion of cyclic prodrug 2 was evaluated in isolated esterase and human plasma in the absence and presence of the esterase inhibitor paraoxon. The rate of hydrolysis of cyclic prodrug 2 was significantly faster in plasma (t(1/2) = 33.5 +/- 0.6 min) than in PBS (t(1/2) = 314 +/- 11 min). Cyclic prodrug 2 was converted by esterase to the parent compound 1 and this conversion was inhibited by an esterase inhibitor, paraoxon. The IC50 (4 muM) of cyclic prodrug 2 was higher than the IC50 (1.9 muM) of parent drug 1. The antithrombic activity of cyclic prodrug 2 depends on the incubation time in platelet-rich plasma; the activity increases with incubation time, suggesting that the prodrug-to-drug conversion is time-dependent and mediated by esterase. Cyclic prodrug 2 was more stable under acidic and neutral conditions than under basic conditions, suggesting that handling and formulation of this prodrug should be undertaken under acidic conditions. (C) 2002 Elsevier Science (USA). All rights reserved.

  DOI：

  10.1016/s0045-2068(02)00013-5
• 作为产物：
  描述：

  对硝基苯酚 、 氯甲酸氯甲酯 生成 氯甲基(4-硝基苯基)碳酸酯
  参考文献：
  名称：

  （酰氧基）烷基氨基甲酸酯作为胺类的新型生物可逆性前药：增加了通过生物膜的渗透性。

  摘要：

  R1R2N-CO-O-CHR3-OCO-R4类型的（酰氧基）烷基氨基甲酸酯被描述为伯胺和仲胺的新型生物可逆性前药。它们可以通过涉及对硝基苯基α-（酰氧基）烷基碳酸酯的亲核攻击并取代对硝基苯酚的一步反应制备，也可以通过α-卤代烷基氨基甲酸酯与羧酸的银或汞盐反应来制备。这些酯氨基甲酸酯中酯键的酶促水解导致级联反应，从而导致母体胺快速再生。阿替洛尔，倍他洛尔，潘多洛尔，普萘洛尔等非离子衍生物的渗透性测量 噻吗洛尔和噻吗洛尔通过模糊的大鼠皮肤和安装在扩散细胞上的兔角膜显示，亲水性β受体阻滞剂的衍生化导致通过这些生物膜的渗透率增加了几倍。然而，亲脂性β-受体阻滞剂的前药修饰导致通透性特性的优势很小。

  DOI：

  10.1021/jm00397a008

文献信息

• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：eXIthera Pharmaceuticals Inc.

  公开号：US20150225389A1

  公开（公告）日：2015-08-13

  The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.

  本发明提供了抑制XIa因子或激肽酶的化合物和组合物，以及使用这些化合物和组合物的方法。
• N-acylamino acid amide compounds and intermediates for preparation thereof
  申请人：Ube Industries, Ltd.

  公开号：US06265418B1

  公开（公告）日：2001-07-24

  The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

  本发明公开了以下公式（I）所表示的化合物： 其中A代表以下公式（a-1）或以下公式（a-2）： B代表以下公式（b）： （其中符号如规范中所定义）或其药学上可接受的盐，以及用于制备其的中间体，具有优异的血小板聚集抑制活性和其他性质，并且可用作与纤维蛋白原受体、血栓形成、梗塞等疾病相关的预防或治疗剂。
• (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10
  申请人：Shionogi & Co., Ltd.

  公开号：US09133216B2

  公开（公告）日：2015-09-15

  The compounds are intermediates in the preparation of therapeutic agents useful in the treatment of viral infections, particularly HIV infection. The compounds are (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenylmethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10.

  这些化合物是制备治疗病毒感染，特别是HIV感染的治疗剂的中间体。这些化合物是P-9式和/或P-10式的(3S,11aR)-6-[(苯甲基)氧基]-3-甲基-2,3,11,11a-四氢噁唑并[3,2-a]吡啶并[1,2-d]吡嗪-5,7-二酮和(3S,11aR)-6-[(苯甲基)氧基]-8-溴-3-甲基-2,3,11,11a-四氢噁唑并[3,2-a]吡啶并[1,2-d]吡嗪-5,7-二酮。
• Prodrugs of GABA analogs, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20060229361A1

  公开（公告）日：2006-10-12

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，GABA类似物前药的药物组合物以及制备GABA类似物前药的方法。本发明还提供了使用GABA类似物前药的方法以及使用GABA类似物前药的药物组合物治疗或预防常见疾病和/或疾病的方法。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。